Hernandez, EM, Maqueda, JC, Fonseca, E, Marco, C, Chico, J, Fernandez, JG, Llaurado, A, Cabello, J, del Pino, L, Izquierdo, C, Cortes, E, G llego, J, Ros, M, Cald , R, Pelayo, A, Vizcaino, CS, Hernandez, H, Alvarez, J, Simo, M, Dalmau, J, Bruna, J, Velasco, R. Immune checkpoint inhibitor-related myositis-myasthenia: A retrospective cohort study in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, AC. Efficacy of Riliprubart in chronic inflammatory demyelinating polyneuropathy: Phase 2 subgroup analyses. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Managing multifocal motor neuropathy: A survey of neurologists from Japan, Canada, and six European countries. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Reyes, V, Maurino, J, Armangu , T, Querol, L, Guti rrez-Guti rrez, G, Sotoca, J, Ares, A, Villaverde, R, Salas, E, D az-Abos, P, Cort s-Vicente, E, Gomez-Ballesteros, R, Ballesteros, J. Psychometric evaluation of resistance to change questionnaire: reluctance to adopt new treatments in myasthenia gravis. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Sacconi, S, Antozzi, C, Cortes-Vicente, E, Pascuzzi, R, Utsugisawa, K, Vissing, J, Vu, T, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Skripuletz, T, Allen, J, Rinaldi, S, Lauria, G, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Stettner, M, Lewis, R, van Doorn, P. Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Vicente, EC, Pease, S, Imran, N, Gandhi, K, Ait-Tihuaty, M, Turkoz, I, Coteur, G, Gary, C, Choudhry, Z, Ramchandran, S, Vissing, J. Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Villaverde, R, Gomez-Ballesteros, R, Reyes, V, Armangue, T, Querol, L, Gutierrez-Gutierrez, G, Sotoca, J, Ares, A, Salas, E, Abos, PD, Squaglia, A, Maurino, J, Cortes-Vicente, E. Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Lewis, RA, Suresh, N, Mazzeo, A, Allen, JA, Querol, L, Hussain, YM, Gwathmey, KG, Guptill, JT, Istas, G, Van Hoorick, B, Mole, T, Kuwabara, S, Basta, I, van Door, PA. SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: SELECTED SECONDARY OUTCOMES FROM THE ADHERE TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. EFFICACY OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: PHASE 2 SUBGROUP ANALYSES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

Falzone, Y, Querol, L, Lewis, R, Hartung, HP, van Doorn, P, Lin, J, Donnie, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, R. SAFETY AND EFFICACY OF RILIPRUBART IN CIDP 76-WEEK PHASE 2 TRIAL RESULTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

De Lorenzo, A, Moretti, GS, Bertini, A, De Lorenzo, A, Vidiella, RC, Falzone, YM, Fortanier, E, Gendre, T, Gentile, F, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mandia, D, Marion, M, Mira, V, Peric, S, Querol, L, Rajabally, Y, Sevilla, T, Tomaselli, PJ, Tozza, S, Bosca, M, Brouwer, M, Cocco, A, Cousyn, L, De Santis, T, Gonzalez, F, Lukic, MJ, Mistry, N, Maranzano, A, Morena, E, Nakano, FN, Saura, GO, Sechi, E, Ticozzi, N, Troisi, S, Tsokkos, T, Aymeric, W, Pisciotta, C, Orazio, EN, Pareyson, D, Doneddu, PE. CHAT-GPT-4O IN DIAGNOSIS AND MANAGEMENT OF REAL-LIFE POLYNEUROPATHY CASES: COMPARATIVE ANALYSIS WITH NEUROLOGISTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

Gallo, C, Doneddu, PE, Collet-Vidiella, R, Cocito, D, Manganelli, F, Falzone, Y, Pinter, GL, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Dalla Bella, E, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

Allen, JA, Door, PAV, Benedetti, L, Basta, I, Dysgaard, T, Eggers, C, Guptill, JT, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, TN, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

Alberti-Vall, B, Olmedo-Saura, G, Domine, M, Borrell-Pichot, M, Avila, MC, Jordana, AV, Pagonabarraga-Mora, J, Kulisevsky, J, Perez, P. Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Leganes, C, Zapata, MJM, Valle, JM, Membrilla, E, Bordon, EA, Palazón, P, Fortes, LM, Núñez, B, Alvarez, N, Pueyo, C, Soria, A, Oviedo, M, Delgado-Espinoza, CE, Antonijoan, RM. Fast-track strategy to shorten hospital stay in acute complicated paediatric appendicitis: protocol of the FTAA clinical trial. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

Delgado-Espinoza, CE, Garcia, CP, Hosey, KA, Pestana, MJC, Lasso, LFC, Arbos, RMA. Non-commercial sponsored clinical trials with medicinal products in Spain since CTIS implementation. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

Pontes, C, Cortes, M, Delgado, CE, Castillo, LF, Amaro, K, Torres, F, Antonijoan, RM. Environmental impact of avoidable tertiary care: earth-caring arguments for decentralizing trials. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

Pontes, C, Cortés, M, de Pando, T, Gomez-Oliveros, B, Antonijoan, RM, Carot-Sans, G, Ramiro, M. Increasing use of gabapentinoids out of their authorised indications. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

Navarro, TDP, Perez, AM, Carot-Sans, G, Martinez, LE, Belis, MV, Nadal, AM, Garcia, CP. Rising alarm on strong opioids in the elderly: a description of utilization and prescription characteristics. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).